AG˹ٷ

STOCK TITAN

[D] iSpecimen Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
D
Rhea-AI Filing Summary

APEI’s Q2-25 10-Q shows solid top-line growth and a sharp earnings rebound. Revenue rose 6.5% YoY to $162.8 m, driven by 7.2% growth at Rasmussen University and 6.1% at APUS, while Hondros grew 10.5%. Cost discipline limited total expense growth to 3.4%, lifting operating income to $7.0 m versus $2.2 m a year ago.

Net income surged to $4.5 m (vs. $0.4 m), but a $3.5 m loss on the June redemption of all preferred shares and $1.3 m dividends produced a $0.3 m net loss available to common holders (-$0.02 EPS). For the six-month period, diluted EPS swung to +$0.39 from -$0.12 as net income jumped to $13.4 m.

Balance sheet/liquidity: Cash climbed to $176.6 m (up $17.6 m YTD) after $51.8 m operating cash flow and $23 m of West Virginia real-estate sales. The $39.7 m preferred redemption and $43.1 m related cash outflow were funded without new debt; term-loan principal remains $96.4 m (9.9% SOFR+550 bp). Net leverage was comfortably within the 2.0× covenant.

Segment trends: APUS delivered $21.4 m operating profit (+17%), offsetting narrower operating losses at RU (-$2.0 m) and HCN (-$0.4 m). Corporate/Other posted a $12.0 m loss, reflecting GSUSA activity and unallocated costs. A definitive agreement to sell GSUSA closed on 25 Jul 25 (post-period).

Key takeaways: Earnings momentum, removal of preferred dividends, stronger cash generation, and pending GSUSA divestiture improve financial flexibility, though nursing-segment losses and higher interest expense remain watch points.

Il 10-Q del secondo trimestre 2025 di APEI mostra una solida crescita dei ricavi e un netto rimbalzo degli utili. I ricavi sono aumentati del 6,5% su base annua, raggiungendo 162,8 milioni di dollari, trainati da una crescita del 7,2% alla Rasmussen University e del 6,1% ad APUS, mentre Hondros è cresciuta del 10,5%. La disciplina nei costi ha limitato la crescita totale delle spese al 3,4%, portando il reddito operativo a 7,0 milioni di dollari rispetto ai 2,2 milioni dell'anno precedente.

L'utile netto è balzato a 4,5 milioni di dollari (da 0,4 milioni), ma una perdita di 3,5 milioni legata al rimborso a giugno di tutte le azioni privilegiate e dividendi per 1,3 milioni hanno prodotto una perdita netta di 0,3 milioni disponibile per gli azionisti ordinari (-0,02 EPS). Nel periodo di sei mesi, l'EPS diluito è passato da -0,12 a +0,39 grazie a un aumento dell'utile netto a 13,4 milioni.

Գ/ܾ徱à: La liquidità è salita a 176,6 milioni di dollari (in aumento di 17,6 milioni da inizio anno) dopo un flusso di cassa operativo di 51,8 milioni e vendite immobiliari in West Virginia per 23 milioni. Il rimborso di 39,7 milioni delle azioni privilegiate e l'uscita di cassa correlata di 43,1 milioni sono stati finanziati senza nuovo indebitamento; il capitale del prestito a termine resta a 96,4 milioni (9,9% SOFR + 550 punti base). La leva finanziaria netta è comodamente entro il covenant di 2,0×.

Tendenze dei segmenti: APUS ha registrato un utile operativo di 21,4 milioni (+17%), compensando le perdite operative più contenute di RU (-2,0 milioni) e HCN (-0,4 milioni). Corporate/Other ha registrato una perdita di 12,0 milioni, riflettendo attività di GSUSA e costi non allocati. Un accordo definitivo per la vendita di GSUSA è stato chiuso il 25 luglio 2025 (dopo il periodo).

Conclusioni chiave: La dinamica degli utili, la rimozione dei dividendi privilegiati, una maggiore generazione di cassa e la prossima cessione di GSUSA migliorano la flessibilità finanziaria, anche se le perdite nel segmento infermieristico e l'aumento degli oneri finanziari restano aspetti da monitorare.

El 10-Q del segundo trimestre de 2025 de APEI muestra un sólido crecimiento en ingresos y una fuerte recuperación en ganancias. Los ingresos aumentaron un 6,5% interanual hasta 162,8 millones de dólares, impulsados por un crecimiento del 7,2% en Rasmussen University y del 6,1% en APUS, mientras que Hondros creció un 10,5%. La disciplina en costos limitó el crecimiento total de gastos al 3,4%, elevando el ingreso operativo a 7,0 millones frente a 2,2 millones del año anterior.

La utilidad neta se disparó a 4,5 millones (vs. 0,4 millones), pero una pérdida de 3,5 millones por el rescate en junio de todas las acciones preferentes y 1,3 millones en dividendos generaron una pérdida neta de 0,3 millones disponible para los accionistas comunes (-0,02 EPS). En el período de seis meses, el EPS diluido pasó de -0,12 a +0,39 debido a que la utilidad neta subió a 13,4 millones.

Balance/liquidez: El efectivo subió a 176,6 millones (un aumento de 17,6 millones en lo que va del año) tras un flujo de caja operativo de 51,8 millones y ventas de bienes raíces en West Virginia por 23 millones. El rescate de 39,7 millones de acciones preferentes y la salida de efectivo relacionada de 43,1 millones se financiaron sin nueva deuda; el principal del préstamo a plazo sigue en 96,4 millones (9,9% SOFR + 550 pb). El apalancamiento neto se mantuvo cómodamente dentro del convenio de 2,0×.

Tendencias de segmentos: APUS generó un beneficio operativo de 21,4 millones (+17%), compensando las menores pérdidas operativas en RU (-2,0 millones) y HCN (-0,4 millones). Corporate/Otros registró una pérdida de 12,0 millones, reflejando la actividad de GSUSA y costos no asignados. Un acuerdo definitivo para vender GSUSA se cerró el 25 de julio de 2025 (post-periodo).

Puntos clave: El impulso en las ganancias, la eliminación de dividendos preferentes, una mayor generación de efectivo y la próxima desinversión de GSUSA mejoran la flexibilidad financiera, aunque las pérdidas en el segmento de enfermería y el aumento de los gastos por intereses siguen siendo áreas a vigilar.

APEI� 2025� 2분기 10-Q 보고서는 견고� 매출 성장� 급격� 수익 반등� 보여줍니�. 매출은 전년 대� 6.5% 증가� 1� 6,280� 달러�, Rasmussen University� 7.2%, APUS� 6.1%, Hondros� 10.5% 성장했습니다. 비용 절제� � 비용 증가율은 3.4%� 그쳐 영업이익은 작년 220� 달러에서 700� 달러� 상승했습니다.

순이익은 450� 달러� 급증했으�(전년 40� 달러), 6월에 모든 우선주를 상환하며 350� 달러 손실� 130� 달러 배당금으� 인해 보통주주에게 귀속되� 순손실은 30� 달러(주당순이� -0.02달러)� 기록했습니다. 6개월 기간 동안 희석 주당순이익은 -0.12달러에서 +0.39달러� 전환되었으며, 순이익은 1,340� 달러� 증가했습니다.

재무/유동�: 현금은 연초 대� 1,760� 달러 증가� 1� 7,660� 달러�, 5,180� 달러� 영업현금흐름� 2,300� 달러� 웨스트버지니아 부동산 매각으로 증가했습니다. 3,970� 달러 우선� 상환� 4,310� 달러 현금 유출은 신규 부� 없이 자금 조달되었으며, 장기 대� 원금은 9,640� 달러(9.9% SOFR+550bp)� 유지되었습니�. 순레버리지� 2.0� 제한� 내에 안정적으� 머물렀습니�.

부문별 동향: APUS� 2,140� 달러� 영업이익(+17%)� 기록하며 RU(-200� 달러)와 HCN(-40� 달러)� 영업손실 감소� 상쇄했습니다. Corporate/Other 부문은 GSUSA 활동� 배분되지 않은 비용으로 1,200� 달러 손실� 기록했습니다. GSUSA 매각� 관� 확정 계약은 2025� 7� 25일에 체결되었습니�(분기 이후).

핵심 요약: 수익 모멘텀, 우선� 배당 제거, 강한 현금 창출, GSUSA 매각 대� 등은 재무 유연성을 개선하지�, 간호 부문의 손실� 증가� 이자 비용은 계속 주의가 필요합니�.

Le rapport 10-Q du deuxième trimestre 2025 d’APEI montre une solide croissance du chiffre d’affaires et un net rebond des bénéfices. Le chiffre d’affaires a augmenté de 6,5 % en glissement annuel pour atteindre 162,8 millions de dollars, porté par une croissance de 7,2 % à Rasmussen University et de 6,1 % à APUS, tandis que Hondros a progressé de 10,5 %. La maîtrise des coûts a limité la croissance totale des dépenses à 3,4 %, portant le résultat opérationnel à 7,0 millions de dollars contre 2,2 millions un an plus tôt.

Le résultat net a bondi à 4,5 millions de dollars (contre 0,4 million), mais une perte de 3,5 millions liée au remboursement en juin de toutes les actions privilégiées et des dividendes de 1,3 million ont conduit à une perte nette de 0,3 million disponible pour les actionnaires ordinaires (-0,02 BPA). Sur six mois, le BPA dilué est passé de -0,12 à +0,39, le résultat net ayant grimpé à 13,4 millions.

Bilan/liquidités : La trésorerie a augmenté à 176,6 millions de dollars (en hausse de 17,6 millions depuis le début de l’année) après un flux de trésorerie opérationnel de 51,8 millions et des ventes immobilières en Virginie-Occidentale de 23 millions. Le remboursement de 39,7 millions d’actions privilégiées et la sortie de trésorerie associée de 43,1 millions ont été financés sans nouvelle dette ; le principal du prêt à terme reste à 96,4 millions (9,9 % SOFR + 550 pb). L’endettement net est confortablement en dessous du covenant de 2,0×.

Tendances par segment : APUS a dégagé un bénéfice opérationnel de 21,4 millions (+17 %), compensant les pertes opérationnelles réduites de RU (-2,0 millions) et HCN (-0,4 million). Corporate/Other a enregistré une perte de 12,0 millions, reflétant les activités de GSUSA et des coûts non alloués. Un accord définitif de vente de GSUSA a été conclu le 25 juillet 2025 (après la période).

Points clés : La dynamique des bénéfices, la suppression des dividendes privilégiés, une génération de trésorerie renforcée et la cession imminente de GSUSA améliorent la flexibilité financière, bien que les pertes dans le segment infirmier et la hausse des charges d’intérêts restent des points de vigilance.

APEI’s 10-Q für Q2-25 zeigt solides Umsatzwachstum und eine deutliche Gewinnrallye. Der Umsatz stieg im Jahresvergleich um 6,5 % auf 162,8 Mio. USD, angetrieben durch ein Wachstum von 7,2 % an der Rasmussen University und 6,1 % bei APUS, während Hondros um 10,5 % zulegte. Kostendisziplin begrenzte das Gesamtausgabenwachstum auf 3,4 %, wodurch das Betriebsergebnis auf 7,0 Mio. USD gegenüber 2,2 Mio. USD im Vorjahr anstieg.

Der Nettogewinn stieg auf 4,5 Mio. USD (vs. 0,4 Mio.), aber ein Verlust von 3,5 Mio. USD aus der Juni-Rückzahlung aller Vorzugsaktien und 1,3 Mio. USD Dividenden führten zu einem Nettoverlust von 0,3 Mio. USD, der den Stammaktionären zur Verfügung steht (-0,02 EPS). Für den Sechsmonatszeitraum drehte das verwässerte Ergebnis je Aktie von -0,12 auf +0,39, da der Nettogewinn auf 13,4 Mio. USD sprang.

Գ/ܾ徱ä: Die Barmittel stiegen auf 176,6 Mio. USD (plus 17,6 Mio. USD seit Jahresbeginn) nach 51,8 Mio. USD operativem Cashflow und 23 Mio. USD aus Immobilienverkäufen in West Virginia. Die Rückzahlung von 39,7 Mio. USD an Vorzugsaktien und der damit verbundene Cash-Abfluss von 43,1 Mio. USD wurden ohne neue Verschuldung finanziert; der Terminkredit bleibt bei 96,4 Mio. USD (9,9 % SOFR + 550 Basispunkte). Die Nettoverschuldung lag komfortabel innerhalb des Covenants von 2,0×.

Segmenttrends: APUS erzielte einen operativen Gewinn von 21,4 Mio. USD (+17 %), der die geringeren operativen Verluste bei RU (-2,0 Mio. USD) und HCN (-0,4 Mio. USD) ausglich. Corporate/Other verbuchte einen Verlust von 12,0 Mio. USD, was die GSUSA-Aktivitäten und nicht zugeordnete Kosten widerspiegelt. Ein endgültiges Verkaufsabkommen für GSUSA wurde am 25. Juli 2025 abgeschlossen (nach Berichtszeitraum).

Wichtige Erkenntnisse: Die Gewinnentwicklung, der Wegfall der Vorzugsdividenden, eine stärkere Cash-Generierung und die bevorstehende GSUSA-Veräußerung verbessern die finanzielle Flexibilität, obwohl Verluste im Pflegebereich und höhere Zinsaufwendungen weiterhin beobachtet werden müssen.

Positive
  • Revenue growth of 6.5% YoY to $162.8 m with all three education segments expanding.
  • Net income jumped to $4.5 m in Q2 and $13.4 m YTD, reversing prior-year weakness.
  • Operating cash flow rose 56% to $51.8 m, boosting cash to $176.6 m.
  • Preferred stock fully redeemed, eliminating $5-6 m annual dividend burden.
  • AG˹ٷ-estate sales generated $23 m, and GSUSA divestiture (closed July 25) streamlines focus and adds further cash.
  • RU & HCN losses narrowed, indicating early traction on turnaround efforts.
Negative
  • Net loss to common shareholders of $0.3 m (-$0.02 EPS) driven by $3.5 m redemption charge.
  • Interest expense increased to $2.0 m YTD amid 9.94% floating-rate debt.
  • Nursing segments (RU/HCN) still generated operating losses totalling $2.4 m in Q2.
  • Total assets declined $32.7 m YTD as asset sales funded financing outflows.
  • Modest revenue growth (6.5%) may limit operating leverage if cost controls falter.

Insights

TL;DR: Revenue up 6.5%, cash up, preferred repaid; core EPS still thin but improving.

APEI posted its second consecutive quarter of revenue acceleration and returned to positive YTD EPS. Gross profit expanded 240 bp as selling and G&A grew slower than sales. The $43 m preferred redemption eliminates a 10% coupon, adding roughly $5 m annual after-tax savings. Importantly, operating cash flow covered capex, dividends, and most of the redemption, leaving $175 m liquidity for bolt-ons or debt reduction. Segment data show APUS remains the earnings engine; nurse-education (RU/HCN) needs further scale to break even, but Q2 losses narrowed meaningfully. At 0.3× net-cash/equity, leverage looks manageable even with SOFR near 5%. Guidance was not provided, yet run-rate margins imply FY25 EPS potential above $0.90 if trends hold.

TL;DR: Solid demand across military and nursing, but RU/HCN profitability still lagging.

Military-focused APUS continues to benefit from stable DoD Tuition Assistance and VA benefits, while nursing enrollment gains drove double-digit revenue growth at HCN. Rasmussen’s 12% revenue lift suggests brand recovery after prior regulatory headwinds, yet operating loss shows campus network still right-sizing. The shift to online and hybrid curricula supports margin upside once fixed campus leases roll off (no new lease losses this quarter). Sale of GSUSA allows management to focus on core accredited degree units. Regulatory exposure remains moderate; release of RU’s $25 m ED LOC underscores improved composite score. Overall trajectory is positive, but sustained execution in nursing programs is essential.

Il 10-Q del secondo trimestre 2025 di APEI mostra una solida crescita dei ricavi e un netto rimbalzo degli utili. I ricavi sono aumentati del 6,5% su base annua, raggiungendo 162,8 milioni di dollari, trainati da una crescita del 7,2% alla Rasmussen University e del 6,1% ad APUS, mentre Hondros è cresciuta del 10,5%. La disciplina nei costi ha limitato la crescita totale delle spese al 3,4%, portando il reddito operativo a 7,0 milioni di dollari rispetto ai 2,2 milioni dell'anno precedente.

L'utile netto è balzato a 4,5 milioni di dollari (da 0,4 milioni), ma una perdita di 3,5 milioni legata al rimborso a giugno di tutte le azioni privilegiate e dividendi per 1,3 milioni hanno prodotto una perdita netta di 0,3 milioni disponibile per gli azionisti ordinari (-0,02 EPS). Nel periodo di sei mesi, l'EPS diluito è passato da -0,12 a +0,39 grazie a un aumento dell'utile netto a 13,4 milioni.

Գ/ܾ徱à: La liquidità è salita a 176,6 milioni di dollari (in aumento di 17,6 milioni da inizio anno) dopo un flusso di cassa operativo di 51,8 milioni e vendite immobiliari in West Virginia per 23 milioni. Il rimborso di 39,7 milioni delle azioni privilegiate e l'uscita di cassa correlata di 43,1 milioni sono stati finanziati senza nuovo indebitamento; il capitale del prestito a termine resta a 96,4 milioni (9,9% SOFR + 550 punti base). La leva finanziaria netta è comodamente entro il covenant di 2,0×.

Tendenze dei segmenti: APUS ha registrato un utile operativo di 21,4 milioni (+17%), compensando le perdite operative più contenute di RU (-2,0 milioni) e HCN (-0,4 milioni). Corporate/Other ha registrato una perdita di 12,0 milioni, riflettendo attività di GSUSA e costi non allocati. Un accordo definitivo per la vendita di GSUSA è stato chiuso il 25 luglio 2025 (dopo il periodo).

Conclusioni chiave: La dinamica degli utili, la rimozione dei dividendi privilegiati, una maggiore generazione di cassa e la prossima cessione di GSUSA migliorano la flessibilità finanziaria, anche se le perdite nel segmento infermieristico e l'aumento degli oneri finanziari restano aspetti da monitorare.

El 10-Q del segundo trimestre de 2025 de APEI muestra un sólido crecimiento en ingresos y una fuerte recuperación en ganancias. Los ingresos aumentaron un 6,5% interanual hasta 162,8 millones de dólares, impulsados por un crecimiento del 7,2% en Rasmussen University y del 6,1% en APUS, mientras que Hondros creció un 10,5%. La disciplina en costos limitó el crecimiento total de gastos al 3,4%, elevando el ingreso operativo a 7,0 millones frente a 2,2 millones del año anterior.

La utilidad neta se disparó a 4,5 millones (vs. 0,4 millones), pero una pérdida de 3,5 millones por el rescate en junio de todas las acciones preferentes y 1,3 millones en dividendos generaron una pérdida neta de 0,3 millones disponible para los accionistas comunes (-0,02 EPS). En el período de seis meses, el EPS diluido pasó de -0,12 a +0,39 debido a que la utilidad neta subió a 13,4 millones.

Balance/liquidez: El efectivo subió a 176,6 millones (un aumento de 17,6 millones en lo que va del año) tras un flujo de caja operativo de 51,8 millones y ventas de bienes raíces en West Virginia por 23 millones. El rescate de 39,7 millones de acciones preferentes y la salida de efectivo relacionada de 43,1 millones se financiaron sin nueva deuda; el principal del préstamo a plazo sigue en 96,4 millones (9,9% SOFR + 550 pb). El apalancamiento neto se mantuvo cómodamente dentro del convenio de 2,0×.

Tendencias de segmentos: APUS generó un beneficio operativo de 21,4 millones (+17%), compensando las menores pérdidas operativas en RU (-2,0 millones) y HCN (-0,4 millones). Corporate/Otros registró una pérdida de 12,0 millones, reflejando la actividad de GSUSA y costos no asignados. Un acuerdo definitivo para vender GSUSA se cerró el 25 de julio de 2025 (post-periodo).

Puntos clave: El impulso en las ganancias, la eliminación de dividendos preferentes, una mayor generación de efectivo y la próxima desinversión de GSUSA mejoran la flexibilidad financiera, aunque las pérdidas en el segmento de enfermería y el aumento de los gastos por intereses siguen siendo áreas a vigilar.

APEI� 2025� 2분기 10-Q 보고서는 견고� 매출 성장� 급격� 수익 반등� 보여줍니�. 매출은 전년 대� 6.5% 증가� 1� 6,280� 달러�, Rasmussen University� 7.2%, APUS� 6.1%, Hondros� 10.5% 성장했습니다. 비용 절제� � 비용 증가율은 3.4%� 그쳐 영업이익은 작년 220� 달러에서 700� 달러� 상승했습니다.

순이익은 450� 달러� 급증했으�(전년 40� 달러), 6월에 모든 우선주를 상환하며 350� 달러 손실� 130� 달러 배당금으� 인해 보통주주에게 귀속되� 순손실은 30� 달러(주당순이� -0.02달러)� 기록했습니다. 6개월 기간 동안 희석 주당순이익은 -0.12달러에서 +0.39달러� 전환되었으며, 순이익은 1,340� 달러� 증가했습니다.

재무/유동�: 현금은 연초 대� 1,760� 달러 증가� 1� 7,660� 달러�, 5,180� 달러� 영업현금흐름� 2,300� 달러� 웨스트버지니아 부동산 매각으로 증가했습니다. 3,970� 달러 우선� 상환� 4,310� 달러 현금 유출은 신규 부� 없이 자금 조달되었으며, 장기 대� 원금은 9,640� 달러(9.9% SOFR+550bp)� 유지되었습니�. 순레버리지� 2.0� 제한� 내에 안정적으� 머물렀습니�.

부문별 동향: APUS� 2,140� 달러� 영업이익(+17%)� 기록하며 RU(-200� 달러)와 HCN(-40� 달러)� 영업손실 감소� 상쇄했습니다. Corporate/Other 부문은 GSUSA 활동� 배분되지 않은 비용으로 1,200� 달러 손실� 기록했습니다. GSUSA 매각� 관� 확정 계약은 2025� 7� 25일에 체결되었습니�(분기 이후).

핵심 요약: 수익 모멘텀, 우선� 배당 제거, 강한 현금 창출, GSUSA 매각 대� 등은 재무 유연성을 개선하지�, 간호 부문의 손실� 증가� 이자 비용은 계속 주의가 필요합니�.

Le rapport 10-Q du deuxième trimestre 2025 d’APEI montre une solide croissance du chiffre d’affaires et un net rebond des bénéfices. Le chiffre d’affaires a augmenté de 6,5 % en glissement annuel pour atteindre 162,8 millions de dollars, porté par une croissance de 7,2 % à Rasmussen University et de 6,1 % à APUS, tandis que Hondros a progressé de 10,5 %. La maîtrise des coûts a limité la croissance totale des dépenses à 3,4 %, portant le résultat opérationnel à 7,0 millions de dollars contre 2,2 millions un an plus tôt.

Le résultat net a bondi à 4,5 millions de dollars (contre 0,4 million), mais une perte de 3,5 millions liée au remboursement en juin de toutes les actions privilégiées et des dividendes de 1,3 million ont conduit à une perte nette de 0,3 million disponible pour les actionnaires ordinaires (-0,02 BPA). Sur six mois, le BPA dilué est passé de -0,12 à +0,39, le résultat net ayant grimpé à 13,4 millions.

Bilan/liquidités : La trésorerie a augmenté à 176,6 millions de dollars (en hausse de 17,6 millions depuis le début de l’année) après un flux de trésorerie opérationnel de 51,8 millions et des ventes immobilières en Virginie-Occidentale de 23 millions. Le remboursement de 39,7 millions d’actions privilégiées et la sortie de trésorerie associée de 43,1 millions ont été financés sans nouvelle dette ; le principal du prêt à terme reste à 96,4 millions (9,9 % SOFR + 550 pb). L’endettement net est confortablement en dessous du covenant de 2,0×.

Tendances par segment : APUS a dégagé un bénéfice opérationnel de 21,4 millions (+17 %), compensant les pertes opérationnelles réduites de RU (-2,0 millions) et HCN (-0,4 million). Corporate/Other a enregistré une perte de 12,0 millions, reflétant les activités de GSUSA et des coûts non alloués. Un accord définitif de vente de GSUSA a été conclu le 25 juillet 2025 (après la période).

Points clés : La dynamique des bénéfices, la suppression des dividendes privilégiés, une génération de trésorerie renforcée et la cession imminente de GSUSA améliorent la flexibilité financière, bien que les pertes dans le segment infirmier et la hausse des charges d’intérêts restent des points de vigilance.

APEI’s 10-Q für Q2-25 zeigt solides Umsatzwachstum und eine deutliche Gewinnrallye. Der Umsatz stieg im Jahresvergleich um 6,5 % auf 162,8 Mio. USD, angetrieben durch ein Wachstum von 7,2 % an der Rasmussen University und 6,1 % bei APUS, während Hondros um 10,5 % zulegte. Kostendisziplin begrenzte das Gesamtausgabenwachstum auf 3,4 %, wodurch das Betriebsergebnis auf 7,0 Mio. USD gegenüber 2,2 Mio. USD im Vorjahr anstieg.

Der Nettogewinn stieg auf 4,5 Mio. USD (vs. 0,4 Mio.), aber ein Verlust von 3,5 Mio. USD aus der Juni-Rückzahlung aller Vorzugsaktien und 1,3 Mio. USD Dividenden führten zu einem Nettoverlust von 0,3 Mio. USD, der den Stammaktionären zur Verfügung steht (-0,02 EPS). Für den Sechsmonatszeitraum drehte das verwässerte Ergebnis je Aktie von -0,12 auf +0,39, da der Nettogewinn auf 13,4 Mio. USD sprang.

Գ/ܾ徱ä: Die Barmittel stiegen auf 176,6 Mio. USD (plus 17,6 Mio. USD seit Jahresbeginn) nach 51,8 Mio. USD operativem Cashflow und 23 Mio. USD aus Immobilienverkäufen in West Virginia. Die Rückzahlung von 39,7 Mio. USD an Vorzugsaktien und der damit verbundene Cash-Abfluss von 43,1 Mio. USD wurden ohne neue Verschuldung finanziert; der Terminkredit bleibt bei 96,4 Mio. USD (9,9 % SOFR + 550 Basispunkte). Die Nettoverschuldung lag komfortabel innerhalb des Covenants von 2,0×.

Segmenttrends: APUS erzielte einen operativen Gewinn von 21,4 Mio. USD (+17 %), der die geringeren operativen Verluste bei RU (-2,0 Mio. USD) und HCN (-0,4 Mio. USD) ausglich. Corporate/Other verbuchte einen Verlust von 12,0 Mio. USD, was die GSUSA-Aktivitäten und nicht zugeordnete Kosten widerspiegelt. Ein endgültiges Verkaufsabkommen für GSUSA wurde am 25. Juli 2025 abgeschlossen (nach Berichtszeitraum).

Wichtige Erkenntnisse: Die Gewinnentwicklung, der Wegfall der Vorzugsdividenden, eine stärkere Cash-Generierung und die bevorstehende GSUSA-Veräußerung verbessern die finanzielle Flexibilität, obwohl Verluste im Pflegebereich und höhere Zinsaufwendungen weiterhin beobachtet werden müssen.

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL
OMB Number: 3235-0076
Estimated average burden
hours per response: 4.00

1. Issuer's Identity

CIK (Filer ID Number) Previous Names
X None
Entity Type
0001558569
X Corporation
Limited Partnership
Limited Liability Company
General Partnership
Business Trust
Other (Specify)

Name of Issuer
iSpecimen Inc.
Jurisdiction of Incorporation/Organization
DELAWARE
Year of Incorporation/Organization
X Over Five Years Ago
Within Last Five Years (Specify Year)
Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer
iSpecimen Inc.
Street Address 1 Street Address 2
8 CABOT ROAD SUITE 1800
City State/Province/Country ZIP/PostalCode Phone Number of Issuer
WOBURN MASSACHUSETTS 01801 781-301-6700

3. Related Persons

Last Name First Name Middle Name
Lim Robert Bradley
Street Address 1 Street Address 2
8 CABOT ROAD SUITE 1800
City State/Province/Country ZIP/PostalCode
WOBURN MASSACHUSETTS 01801
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Field Katharyn
Street Address 1 Street Address 2
8 CABOT ROAD SUITE 1800
City State/Province/Country ZIP/PostalCode
WOBURN MASSACHUSETTS 01801
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

President
Last Name First Name Middle Name
Yang Siyun
Street Address 1 Street Address 2
8 CABOT ROAD SUITE 1800
City State/Province/Country ZIP/PostalCode
WOBURN MASSACHUSETTS 01801
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Lau Anthony
Street Address 1 Street Address 2
8 CABOT ROAD SUITE 1800
City State/Province/Country ZIP/PostalCode
WOBURN MASSACHUSETTS 01801
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Dhaliwal Avtar
Street Address 1 Street Address 2
8 CABOT ROAD SUITE 1800
City State/Province/Country ZIP/PostalCode
WOBURN MASSACHUSETTS 01801
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


4. Industry Group

Agriculture
Banking & Financial Services
Commercial Banking
Insurance
Investing
Investment Banking
Pooled Investment Fund
Is the issuer registered as
an investment company under
the Investment Company
Act of 1940?
Yes No
Other Banking & Financial Services
Business Services
Energy
Coal Mining
Electric Utilities
Energy Conservation
Environmental Services
Oil & Gas
Other Energy
Health Care
Biotechnology
Health Insurance
Hospitals & Physicians
Pharmaceuticals
Other Health Care
Manufacturing
AG˹ٷ Estate
Commercial
Construction
REITS & Finance
Residential
Other AG˹ٷ Estate
Retailing
Restaurants
Technology
Computers
Telecommunications
Other Technology
Travel
Airlines & Airports
Lodging & Conventions
Tourism & Travel Services
Other Travel
X
Other

5. Issuer Size

Revenue Range OR Aggregate Net Asset Value Range
No Revenues No Aggregate Net Asset Value
$1 - $1,000,000 $1 - $5,000,000
$1,000,001 - $5,000,000 $5,000,001 - $25,000,000
$5,000,001 - $25,000,000 $25,000,001 - $50,000,000
$25,000,001 - $100,000,000 $50,000,001 - $100,000,000
Over $100,000,000 Over $100,000,000
X Decline to Disclose Decline to Disclose
Not Applicable Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))
Rule 504 (b)(1)(i)
Rule 504 (b)(1)(ii)
Rule 504 (b)(1)(iii)
X Rule 506(b)
Rule 506(c)
Securities Act Section 4(a)(5)
Investment Company Act Section 3(c)
Section 3(c)(1) Section 3(c)(9)
Section 3(c)(2) Section 3(c)(10)
Section 3(c)(3) Section 3(c)(11)
Section 3(c)(4) Section 3(c)(12)
Section 3(c)(5) Section 3(c)(13)
Section 3(c)(6) Section 3(c)(14)
Section 3(c)(7)

7. Type of Filing

X New Notice Date of First Sale 2025-08-01 First Sale Yet to Occur
Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?
Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity Pooled Investment Fund Interests
Debt Tenant-in-Common Securities
X Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor $0 USD

12. Sales Compensation

Recipient
Recipient CRD Number None
Westpark Capital, Inc 000039914
(Associated) Broker or Dealer X None
(Associated) Broker or Dealer CRD Number X None
None None
Street Address 1 Street Address 2
535 5TH Ave 22nd FL
City State/Province/Country ZIP/Postal Code
New York NEW YORK 10017
State(s) of Solicitation (select all that apply)
Check "All States" or check individual States
All States
Foreign/non-US
DELAWARE
FLORIDA

13. Offering and Sales Amounts

Total Offering Amount $1,750,000 USD
or Indefinite
Total Amount Sold $1,750,000 USD
Total Remaining to be Sold $0 USD
or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
4

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions $70,000 USD
X Estimate
Finders' Fees $0 USD
Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$0 USD
X Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:
  • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
  • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
  • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer Signature Name of Signer Title Date
iSpecimen Inc. /s/ Katharyn Field Katharyn Field President 2025-08-06

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


FAQ

How much revenue did APEI (APEI) report for Q2 2025?

APEI generated $162.8 million in revenue for the quarter ended 30 Jun 25, up 6.5% year over year.

Did APEI earn a profit in the second quarter of 2025?

Yes. Net income was $4.5 million; however, after preferred dividends and redemption cost, the quarter showed a $0.3 million loss attributable to common shareholders.

What is APEI’s current cash position and debt level?

As of 30 Jun 25, cash and equivalents were $176.6 million; long-term term-loan debt remained $96.4 million maturing in 2027.

How did segment performance vary in Q2 2025 for APEI?

APUS earned $21.4 m operating income, while Rasmussen University and Hondros College posted operating losses of $2.0 m and $0.4 m, respectively.

What was the impact of the preferred stock redemption?

APEI paid $43.1 m to redeem all preferred shares, recorded a $3.5 m loss, and will avoid future dividends of roughly $2.7 m per half-year.

Has the sale of Graduate School USA been completed?

Yes. The company closed the divestiture of GSUSA on 25 Jul 25, after the quarter-end, allowing greater strategic focus on core degree programs.
Ispecimen Inc.

NASDAQ:ISPC

ISPC Rankings

ISPC Latest News

ISPC Latest SEC Filings

ISPC Stock Data

5.77M
2.43M
2.71%
2.41%
1.91%
Diagnostics & Research
Services-commercial Physical & Biological Research
United States
WOBURN